Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.
The myeloproliferative diseases (MPDs) present several therapeutic challenges in patients of childbearing potential. The most extensive literature exists for patients with essential thrombocythaemia, with over 200 pregnancies reported in retrospective case series. Yet there is conflicting data in relation to predicting pregnancy outcome and optimal management strategy. Pregnancy is less frequently reported for polycythaemia vera and myelofibrosis. There is a need for collaboration to further our knowledge in this field. Here, the literature is reviewed in detail and experience of different therapeutic strategies in pregnancy discussed. There is increasing understanding about the pathogenesis of placental dysfunction in inherited thrombophilia and antiphospholipid antibody syndrome pregnancy outcomes in these conditions parallel those reported for MPDs. Furthermore several large studies have influenced pregnancy management in these conditions and, whilst not directly applicable to MPDs, this data have potential to inform treatment protocols. This data are reviewed and a personal management strategy for pregnancy in MPD proposed.
Harrison
Claire
C
Department of Haematology, Guy's and St Thomas' Foundation Trust, St Thomas' Hospital, London SE1 7EH, UK. claire.harrison@gstt.sthames.nhs.uk
D005260:Female; D006801:Humans; D009196:Myeloproliferative Disorders / Q000235:genetics / Q000628:therapy*; D010677:Philadelphia Chromosome; D011087:Polycythemia Vera / Q000628:therapy; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000628:therapy*; D011256:Pregnancy Outcome; D055728:Primary Myelofibrosis / Q000628:therapy; D013920:Thrombocythemia, Essential / Q000628:therapy